elobixibat
Small moleculeexperimental
Elobixibat is an inhibitor of the ileal bile acid transporter (IBAT), undergoing development in clinical trials for the treatment of chronic constipation and irritable bowel syndrome with constipation (IBS-C). — Wikipedia
Clinical trial activity
14 trials · 10 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
10
Phase 3
4
Phase 4
3
Earliest trial started Nov 1, 2009 (NCT01007123)
Timeline
Indications
Approved for
Mechanism of action
- Ileal bile acid transporterINHIBITOR
SLC10A2 inhibitor
Inhibits ileal bile acid reuptake via the inhibition of Ileal sodium/bile acid cotransporter
Chemistry & pharmacology
Loading structure…
SMILES
CCCCC1(CCCC)CN(c2ccccc2)c2cc(SC)c(OCC(=O)N[C@@H](C(=O)NCC(=O)O)c3ccccc3)cc2S(=O)(=O)C1- Mol. weight
- 695.9 g/mol
- Lipinski Ro5
- 2 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaElobixibat ↗
- ChEMBLCHEMBL3039515 ↗
Also known as
- a3309
- a3309
- a3309
- a-3309
- azd-7806
- azd-7806
- elobixibat
- elobixibat
- elobixibat
- elobixibat
- elobixibat
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06436833 | N/A | May 24, 2024 | Rajavithi Hospital, Bangkok |
| NCT05703464 | Phase 4 | Feb 9, 2023 | International University of Health and Welfare |
| NCT05165199 | Phase 4 | Jan 31, 2022 | Yokohama City University |
| NCT05895877 | Phase 3 | Dec 21, 2021 | National Taiwan University, Synmosa Biopharma Corp. |
| NCT04784780 | Phase 4 | Aug 6, 2021 | Yokohama City University |
| NCT04235205 | Phase 2 | Feb 1, 2020 | EA Pharma Co., Ltd., Yokohama City University |
| NCT04006145 | Phase 2 | Jun 6, 2019 | Albireo |
| NCT02392546 | Phase 2 | Apr 1, 2015 | Ferring |
| NCT01895543 | Phase 3 | Sep 1, 2013 | Ferring |
| NCT01833065 | Phase 3 | Apr 1, 2013 | Ferring |
| NCT01827592 | Phase 3 | Apr 1, 2013 | Ferring |
| NCT01069783 | Phase 2 | Feb 1, 2010 | Albireo |
| NCT01038687 | Phase 2 | Jan 1, 2010 | Mayo Clinic, National Center for Research Resources (NCRR) |
| NCT01007123 | Phase 2 | Nov 1, 2009 | Albireo |
Showing 14 of 14 trials
Page 1 / 1
Organizations
Research & Development (10)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Ferring | For profit | 4 | 4 | 2 | 2013 |
| Albireo | For profit | 3 | 3 | 1 | 2009 |
| Yokohama City University | Academic/Hospital | 3 | 3 | 2 | 2020 |
| EA Pharma Co., Ltd. | For profit | 1 | 0 | 1 | 2020 |
| International University of Health and Welfare | Academic/Hospital | 1 | 1 | 1 | 2023 |
| Mayo Clinic | Academic/Hospital | 1 | 1 | 1 | 2010 |
| National Center for Research Resources (NCRR) | Government | 1 | 0 | 1 | 2010 |
| National Taiwan University | Academic/Hospital | 1 | 0 | 1 | 2021 |
| Rajavithi Hospital, Bangkok | Academic/Hospital | 1 | 1 | 1 | 2024 |
| Synmosa Biopharma Corp. | For profit | 1 | 1 | 1 | 2021 |
10 organizations
Page 1 / 1